News | February 15, 2025
Bristol Myers Squibb Provides Update on Phase 3 RELATIVITY-098 Trial
The safety profile of Opdualag observed in this analysis was consistent with the known profiles of nivolumab and relatlimab
The safety profile of Opdualag observed in this analysis was consistent with the known profiles of nivolumab and relatlimab
Revenue up 11% to Rs 5,768 crore as compared to Rs 5,197 crore
Total Income during Q3 FY25 stood at Rs. 527.37 crore as compared to Rs. 528.77 crore in Q3 FY24
The company has withdrawn all litigation against Vikas Lifecare Limited post withdrawal of the Alwar Case by VLL
The company will offer end-to-end services and solutions for the sector with a specific focus on sustainability
He has over 23 years of experience across sectors
During the quarter, the company posted Revenue from operations at Rs. 5,269 crore as compared to Rs. 4,505 crore in Q3 FY25, posting a growth of 17 per cent
Wockhardt also saw its revenue from operations increased 3% to Rs. 721 crore during Q3 FY25
During the quarter, US formulations revenue decreased by 2.3% YoY to Rs. 3,671 crore.
EMBLAVEOTM is the first and only monobactam/?-lactamase inhibitor combination antibiotic therapy approved by the USFDA
Subscribe To Our Newsletter & Stay Updated
